Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin

Philipp Baumeister a Maximilian Reiter a Sabina Schwenk-Zieger b Ulrich Harréus a

a Department of Otolaryngology and Head and Neck Surgery, and b Clinical Experimental Oncology, Department of Otolaryngology and Head and Neck Surgery, Ludwig Maximilian University, Munich, Germany

Key Words
Chemoresistance to cisplatin · Transforming growth factor α stimulation · Head and neck squamous cell carcinoma

Abstract
The monoclonal epidermal growth factor receptor (EGFR) antibody cetuximab (Erbitux™) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination with a platinum-based chemotherapy. Since the antibody has only a limited effect as a monotherapy, possible explanations for the synergistic effect with cisplatin are enhanced antibody-dependent cytotoxicity and increased sensitivity to the drug. Most of our knowledge of EGFR biology in HNSCC is based on studies using EGFR inhibitors and/or antibodies. Our study was designed to evaluate the impact of EGFR stimulation on cisplatin-induced DNA damage. Therefore, tissue cultures were produced of tumor-free oropharyngeal mucosa biopsies of HNSCC patients and controls. In a previous study, overexpression of EGFR in tissue cultures from tumor patients compared to controls was confirmed by immunohistochemical staining. Twenty-four-hour stimulation of tissue cultures with transforming growth factor α (TGF-α), a specific EGFR ligand, resulted in a reduction of cisplatin-induced DNA damage by 35% in cases, whereas in controls TGF-α had no effect. This reflects a statistically significant increase in cellular chemoresistance to cisplatin following TGF-α stimulation and helps to further understand effects of EGFR antisense therapy in combination with chemotherapy.

Introduction
Epidermal growth factor receptor (EGFR)-targeting therapeutics represent a major improvement in the treatment of recurrent or metastatic squamous cell carcinoma in the head and neck (HNSCC). The rationale behind this is based on several findings:

(a) the inhibition of EGFR signaling was shown to effectively decrease the proliferation rate using various EGFR-overexpressing cell lines [1];
(b) HNSCC exhibits EGFR overexpression in up to 90% of tumors [2];

The results of this study were partially presented at the 80th annual meeting of the German Society of Otorhinolaryngology, Head and Neck Surgery.
specific inhibitors of signal transducers like rapamycin standing of this ‘fine-tuning’ will help to develop more 
cle arrest or proliferation. In the future, further under-
signaling, which lies downstream of 
[13]
Tarceva™ are currently under clinical investigation for 
HNSCC when combined with radiotherapy. Drugs tar-
and to diminish angiogenesis in various tumor models 
was shown to inhibit cell proliferation and decrease cell 
ment of EGFR antisense therapeutics was widely based on 
the treatment of HNSCC.

In this context, it is important to note that the develop-
ment of EGFR antisense therapeutics was widely based on 
observations made after EGFR inhibition. Cetuximab 
was shown to inhibit cell proliferation and decrease cell survival, to reduce cellular motility and tumor invasion and to diminish angiogenesis in various tumor models [6–10].

EGFR activation, on the other hand, did not lead to 
consistent results. In a recent study, Song et al. [11] could 
show that EGF induces apoptosis in 3 carcinoma cell 
lines and that the ligand has more cytotoxic potential 
than EGFR blockers in these receptor-overexpressing 
cell lines. Studies showing that ligand-induced EGFR 
activation leads to apoptosis are reviewed by Danielsen 
and Maihle [12]. As summarized by McCubrey et al. [13], what they call ‘fine-tuning’ of the Raf/MEK/ERK 
signal transduction pathway, which lies downstream of 
EGFR activation, dictates whether there will be cell cy-
cle arrest or proliferation. In the future, further under-
standing of this ‘fine-tuning’ will help to develop more 
specific inhibitors of signal transducers like rapamycin [14].

Recently, Vermorken et al. [15] reported the efficacy of 
cetuximab in combination with a platinum-based che-
motherapy as first-line treatment of recurrent or meta-
static HNSCC. Possible explanations for the synergistic 
effects include enhanced antibody-dependent cytotoxic-
ity and enhanced chemosensitivity [16, 17].

It is an important feature of EGFR biology in HNSCC 
that the receptor is continuously activated by EGF-related 
growth factors produced by either the tumor cells them-
selves or surrounding stromal cells [18]. Interestingly, 
increased expression of EGFR and its specific ligand-forming growth factor α (TGF-α) was detected in histor-
logically normal mucosa of HNSCC patients compared to non-tumor patients [19].

Our study evaluates the impact of TGF-α stimulation 
of human mucosal tissue cultures of tumor and control 
patients on cisplatin-induced DNA damage using the 
alkaline single-cell microgel electrophoresis (comet) assay.

**Materials and Methods**

**Mini-Organ Cultures**

The study was approved by the ethics committee of Ludwig Maximilian University, Munich, Germany (project 349-05). All biopsy donors were informed by the investigators and signed an informed consent statement.

We prepared mini-organ cultures (MOC) from fresh biopsied oropharyngeal mucosa samples from tumor and control patients. Samples were harvested during resection of oropharyngeal squa-

mous cell carcinomas and tonsillectomy, respectively. Biopsies of 
tumor patients were taken from macroscopically normal mucosa close to the tumor-free resection margins. In a previous study, 
EGFR overexpression of MOC from tumor patients was con-
firmed by immunohistochemical staining (data not shown).

Specimens were dissected into cubes of 1 mm³ excluding deep-
er layers and washed three times in bronchial epithelial cell basal medium (BEGM; supplemented with bovine pituitary extract, in-
sulin, hydrocortisone, epinephrine, triiodothyronine, transferrin 
and retinoic acid; Promocell, Heidelberg, Germany). Cubes were 
placed in 24-well plates, 1 each well, and coated with 0.75% Agar 
and retinoic acid; Promocell, Heidelberg, Germany). Cubes were 
placed in 24-well plates, 1 each well, and coated with 0.75% Agar 
Noble (Difco, Detroit, Mich., USA) and dissolved in Dulbecco’s modified Eagle’s medium (Gibco, Eggenstein, Germany), 10% fe-
tal calf serum (Gibco), nonessential amino acids (Gibco) and am-
photericin B (Gibco). After about 20 days in 250 µl BEGM, each 
well at 37.5 °C, 5% CO₂ and 100% relative humidity, MOC were 
completely coated with epithelium. BEGM was replaced every 
second day during cultivation. Every seventh day, multwell plates 
were changed to avoid adherence [20]. As seen in figure 1, after 
complete epithelialization, the majority of cells within the MOC 
is of epithelial origin, and there is only a limited number of stromo-
al cells, vessels and glands. The model of MOC has several ad-

dantages compared to cell line experiments or animal models. In 
MOC, cells stay in their original surrounding tissue, which might 
have an impact on their metabolic competence [21, 22]. Further-
more, standardized conditions can be applied. However, during 
the culturing process, additional oxidative stress and DNA dam-
age occurs [23].

**Cisplatin-Induced DNA Damage**

Cisplatin is well known to produce interstrand cross-links 
within the DNA. Since the alkaline single-cell microgel electrophoresis assay is able to detect DNA strand breaks, hydrogen per-
oxide (H₂O₂) was used to introduce random DNA fragmentation. 
Therefore, cisplatin-induced DNA cross-links reduced migration 
of DNA fragments compared to untreated DNA as measured with 
the comet assay [24].

---

1. http://www.emea.europa.eu/humandocs/PDFs/EPAR/erbitux/H-558-
.htm.

---

Increase in Chemoresistance to Cisplatin following TGF-α Stimulation
MOC were stimulated with TGF-α (100 ng/ml) dissolved in dimethyl sulfoxide (DMSO; Merck, Darmstadt, Germany) for 24 h. MOC were then washed twice before incubation with cisplatin (10 μM; dissolved in DMSO) for another 24 h. This concentration was previously shown to induce sufficient DNA cross-links without inducing apoptosis in cell cultures [24]. Thereafter, H₂O₂ (1 mM) induced random DNA fragmentation within 15 min. MOC were finally washed again twice. All incubations were carried out at 37.5°C, 5% CO₂ and 100% relative humidity.

Alkaline Single-Cell Microgel Electrophoresis (Comet) Assay

MOC were digested enzymatically thus gaining single cells. As stated before, the majority of these cells are epithelial cells [20]. Enzyme suspension included collagenase P (Boehringer, Mannheim, Germany; 1 mg/ml), hyaluronidase (Boehringer; 1 mg/ml) and protease (Sigma; 5 mg/ml). MOC were suspended for 60 min at 37.5°C. After neutralizing histolytic enzymes with fetal calf serum (Gibco), single cells were washed twice in cold phosphate-buffered saline (Gibco), followed by trypan blue exclusion test to monitor cell viability.

Single cells were resuspended in 75 μl 0.7% low-melting agarose (FMC Bioproducts, Rockland, Me., USA) and the suspension was evenly distributed on slides between 2 layers of 85 μl 0.5% normal-melting agarose (FMC Bioproducts). For better adhesion, slides had 5 mm frosted edges. Lysis of cellular and nuclear membranes was performed under alkaline conditions in a solution containing 2.5 M NaCl (Sigma), 10 mM Trizma base (Merck), 100 mM Na₂ EDTA (Serva, Heidelberg, Germany) and 1% N-lauroyl-sarcosine sodium salt (Sigma) at pH 10, with 1% Triton X-100 (Sigma) and 10% DMSO (Merck) added just before use. Subsequently, slides were positioned in a horizontal electrophoresis chamber (Renner, Dannstadt, Germany), close to the anode. Slides were covered with a 4°C cold alkaline buffer solution (pH 13.2) consisting of 300 mM NaOH (Merck) and 1 mM Na₂ EDTA (Serva).

The DNA unwinded for 20 min before migration within an electric field (25 V, 1.0 V/cm, 300 mA, 20 min). Alkaline buffer was now neutralized with Trizma base solution (Merck; 400 mM, pH 7.5). Fluorescent DNA staining was performed with 75 μl ethidium bromide (Sigma). After staining, slides were analyzed with a DMLB microscope (Leica, Bensheim, Germany). Eighty cell nuclei per slide were selected at random and digitized with the attached monochrome CCD camera (Cohu Inc., San Diego, Calif., USA). DNA migration was measured by the image analysis software Komet++ (Kinetic Imaging, Liverpool, UK) using olive tail moments (OTM). OTM represents the multiplication of the relative amount of DNA in the tail with the median migration distance and is commonly used to measure comet assay results not giving any units.

Statistical Analysis

Significant differences in DNA damage between the samples were calculated by the Friedman test using SPSS 16.0 software (SPSS GmbH, Munich, Germany). Calculation was based on the arithmetic mean of 80 OTM of each slide; the α level was set at 0.05 prior to statistical analysis.

Results

After all treatments, cell viability was >90% as assessed by the trypan blue exclusion test.

The solvent DMSO served as negative control and average OTM was 0.74 in controls and 0.86 in cases, reflecting minor DNA damage occurring during the cultivation process [25]. As expected, cisplatin did not lead to detectable DNA fragmentation using the alkaline version of the
comet assay. OTM was 0.84, with and without preliminary stimulation with TGF-α in the non-tumor group. In cases, OTM was 0.77 without, and 0.76 after TGF-α stimulation (fig. 2).

In controls, H₂O₂ caused DNA damage with an average OTM of 9.7, which is statistically significant compared to negative control (p < 0.001). Stimulation with TGF-α did not significantly change H₂O₂-induced DNA fragmentation, which is reflected by OTM 8.8. To evaluate cisplatin-induced DNA cross-links, the introduction of random DNA strand breaks is necessary. Therefore, MOC were incubated with H₂O₂ for 15 min. Lower OTM values then reflect higher levels of cisplatin-induced cross-links as linked DNA hardly dissociates during electrophoresis [24]. In controls, after prior incubation with cisplatin, average OTM due to H₂O₂-induced DNA fragmentation was 4.35. Compared to OTM 9.7 without pretreatment with cisplatin, this shows significant cross-linking levels (p < 0.001). In this group, previous stimulation of MOC with TGF-α for 24 h did not significantly alter DNA cross-linking by cisplatin (OTM = 4.23; fig. 3).

In cases, DNA damage caused by H₂O₂ was not influenced by TGF-α stimulation. OTM induced by H₂O₂ significantly decreased from 12.5 to 5.9 when MOC were previously treated with cisplatin due to cross-linking (p < 0.001). Here, 24-hour stimulation with TGF-α before adding cisplatin significantly reduced DNA cross-links, which is reflected in increased OTM to 8 (p = 0.025; fig. 4).

**Discussion**

Our results show that TGF-α effectively reduces the ability of cisplatin to induce DNA cross-links. This effect could only be shown in MOC produced from macroscopically normal oropharyngeal mucosa samples of tumor patients, whereas TGF-α had no impact on H₂O₂-induced DNA fragmentation in controls. TGF-α had no effect on DNA damage induced by H₂O₂ in either group.

Cisplatin forms interstrand cross-link adducts on DNA, it interferes with DNA synthesis and activates cell death pathways [26]. Therefore, possible explanations for our observation would be the reduction of cross-link formation by reduced intracellular accumulation. Cisplatin enters the cell mostly by passive diffusion, although active transportation might facilitate intracellular accumu-
inside the cell, cisplatin is believed to react with a multitude of non-DNA targets, such as proteins and the cytoskeleton. The most important non-DNA target is glutathione. Cell line experiments showed inversely correlated intracellular glutathione levels and cisplatin sensitivity. Furthermore, there seems to be a connection between extracellular ATP levels and cytotoxic effects of cisplatin.

More recently, transporter proteins of the ABC family on the cellular surface were shown to confer drug resistance. There is growing evidence that cisplatin is a substrate of efflux pumps on the plasma membrane, extruding the drug from the cell. This happens in two phases. The so-called phase 0 'preemptive pumping' describes the elimination of cisplatin before it can react with cellular components immediately after entering the cell. The multidrug resistance protein 2 (cMoat) was shown to confer resistance to cisplatin and overexpression of multidrug resistance protein 2 has been described in at least 1 cisplatin-resistant cell line. In addition, after conjugation with glutathione, the complex is a substrate of the glutathione S-conjugate efflux pump during phase 3 metabolism.

The exact mechanism of how TGF-α stimulation altered cisplatin sensitivity in our study remains unclear. Since the growth factor had no influence on H₂O₂-induced DNA fragmentation, major effects on cellular glutathione levels are unlikely. In a previous study in our laboratory, MOC were incubated with benzo(a)pyrene diol epoxide, a well-established carcinogen, that – like cisplatin – forms DNA adducts. Benzo(a)pyrene diol epoxide is likewise detoxified via conjugation with glutathione. In this study, TGF-α did not affect DNA repair capacity.

There is increasing evidence that EGFR downstream signaling pathways play a major role in the development of chemoresistance, even though experimental results are in part contradictory. While Garcia et al. showed that stimulation of MCF-7 breast cancer cells with EGF (a specific EGFR ligand) induced the expression of genes involved in drug resistance, Mandic et al. found that cisplatin resistance of UT-SCC-26A head and neck cancer cells can be overcome after EGF stimulation. Using the same cell line, the latter group previously showed that EGFR inhibition by cetuximab significantly reduces cisplatin IC₅₀.

In contrast to most studies evaluating the influence of EGFR signaling in cisplatin resistance using cell lines and animal models, we used freshly biopsied tissue samples. Our results clearly show that simulation with TGF-α, a specific EGFR ligand, significantly reduces the ability of cisplatin to form DNA cross-links in MOC pro-
duce of macroscopically normal mucosa of HNSCC patients, which was previously shown to overexpress EGFR [19]. Immunohistochemical staining of MOC slides from these patients in our laboratory confirmed this finding (data not shown). The results presented here are consistent with clinical studies that showed the benefit of EGFR targeting in combination with a platinum-based chemotherapy [15]. Possible influence of TGF-α on the expression and/or function of cisplatin efflux pumps are currently under investigation in our laboratory.

References


4 Nishio K, Aroa T, Kato T: EGFR mutation in these patients in our laboratory confirmed this finding (data not shown). The results presented here are consistent with clinical studies that showed the benefit of EGFR targeting in combination with a platinum-based chemotherapy [15]. Possible influence of TGF-α on the expression and/or function of cisplatin efflux pumps are currently under investigation in our laboratory.

Increase in Chemoresistance to Cisplatin following TGF-α Stimulation

Chemotherapy 2010;56:268–274

273